Next-generation sequencing has yielded transformative insights for population health studies, but now the returns of sequencing more genomes are diminishing. We enable you to expand exploration to the dynamic aspects of disease across population-scale cohorts through the rapid, large-scale profiling of dynamic biomarkers.
We capture metabolites, lipids, and proteins which read out non-genetic factors influencing health, disease, and drug response.
With the ability to process >5K samples per day, we have the scale and efficiency required for population-level analysis.
Built to generate population-scale datasets, our systems are backed by rigorous quality control processes for large-scale analyses.
We maintain the same fast turnaround times for data and insight delivery for even the biggest large-scale projects.
The addition of dynamic biomarkers in population health studies will enable pivotal advancements to deepen our understanding of the non-genetic factors underlying health and disease across heterogeneous human cohorts.
With Sapient’s next-generation rLC-MS systems, now there is finally an efficient, scalable approach to go beyond the genome and enable large-scale discovery of metabolite, lipid, and protein biomarkers that read out these influences.
Many population health studies have focused on genomics to date, yet >80% of disease risk is non-genetic.
With large-scale profiling of small molecule biomarkers, which read out these non-genetic influences, we can enhance the impact of genomics data that has already been captured, adding complementary information to elucidate the interplay between genotype and phenotype across individuals.
Proteins hold critical information on gene expression and function, making proteomics a natural next step to expand population health studies beyond genomics to elucidate functional mechanisms underlying disease.
Sapient’s /HT/ Discovery proteomics is our high throughput method and ideal for population health cohorts in that it enables measurement specificity at scale – capturing thousands of proteins per sample, across thousands of samples per week.
Sapient’s Human Biology Database shows our ability to support population health analyses firsthand. Given the speed of our technologies, we have already generated rLC-MS data in more than 100,000 human biosamples collected from diverse individuals around the world.
With large-scale profiling of small molecule biomarkers, which read out these non-genetic influences, we can help you improve disease understanding and in turn, the precision and efficacy of treatments.
Are their specific metabolite, lipid, or protein biomarkers that you’d like to explore in your cohort? We can often provide solutions for difficult-to-measure biomarkers, or will work with you to define the ideal profiling approach based on your samples and study objectives.
Through our CLIA-certified, CAP-accredited clinical laboratory, we can also support the development of population health biomarker discoveries into diagnostic assays.
Sapient is well-versed in generating, handling, processing, and analyzing large-scale, population-level datasets. We’ve already done so through the development of our proprietary Human Biology Database.
Comprised of rLC-MS data and paired phenotypic measures collected in 100,000+ human biosamples, we can use the database to mine for or validate discoveries in large, independent human populations.
biosample datasets collected from diverse individuals
phenotypic data points linked to spectral data
of follow-up and outcomes data across individuals
10421 Wateridge Circle, Suite 100
San Diego, CA 92121
discover@sapient.bio
858.290.7010
© 2024 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY, and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
